Sue Desmond-Hellmann

Person ● Covered in 1 story + Follow ✴ AI Graph Request update Wikipedia

Sue Desmond-Hellmann is an American oncologist and biotechnology leader who serves on the board of directors of OpenAI, a position she was elected to in March 2024. She previously served as chief executive officer of the Bill & Melinda Gates Foundation from 2014 to 2020. Before that, she was Chancellor of the University of California, San Francisco, the first woman to hold that position, and held the title of Arthur and Toni Rembe Rock Distinguished Professor. Earlier in her career, she was president of product development at Genentech, where she played a role in the development of the gene-targeted cancer drugs Avastin and Herceptin. She joined the OpenAI board alongside Nicole Seligman and Fidji Simo as part of an expansion of new board members.

Updated 6 August 2026

Public sources: Wikipedia

Why this page exists, and how to correct or remove it

This profile is assembled automatically because Sue Desmond-Hellmann appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.

We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.

Claim or correct this profile Request removal How we handle personal data